Cargando…
Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study
There is need for a brief but comprehensive objective assessment tool to help clinicians evaluate relapse symptoms in patients with multiple sclerosis (MS) and their impact on daily functioning, as well as response to treatment. The 2-part Assessing Relapse in Multiple Sclerosis (ARMS) questionnaire...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677606/ https://www.ncbi.nlm.nih.gov/pubmed/23766909 http://dx.doi.org/10.1155/2013/470476 |
_version_ | 1782272743611301888 |
---|---|
author | Perrin Ross, Amy Williamson, Alona Smrtka, Jennifer Flemming Tracy, Tracy Saunders, Carol Easterling, Constance Niewoehner, John Mutschler, Nicole |
author_facet | Perrin Ross, Amy Williamson, Alona Smrtka, Jennifer Flemming Tracy, Tracy Saunders, Carol Easterling, Constance Niewoehner, John Mutschler, Nicole |
author_sort | Perrin Ross, Amy |
collection | PubMed |
description | There is need for a brief but comprehensive objective assessment tool to help clinicians evaluate relapse symptoms in patients with multiple sclerosis (MS) and their impact on daily functioning, as well as response to treatment. The 2-part Assessing Relapse in Multiple Sclerosis (ARMS) questionnaire was developed to achieve these aims. Part 1 consists of 7 questions that evaluate relapse symptoms, impact on activities of daily living (ADL), overall functioning, and response to treatment for previous relapses. Part 2 consists of 7 questions that evaluate treatment response in terms of symptom relief, functioning, and tolerability. The ARMS questionnaire has been evaluated in 103 patients with MS. The most commonly reported relapse symptoms were numbness/tingling (67%), fatigue (58%), and leg/foot weakness (55%). Over half of patients reported that ADL or overall functioning were affected very much (47%) or severely (11%) by relapses. Prescribed treatments for relapses included intravenous and/or oral corticosteroids (87%) and adrenocorticotropic hormone (13%). Nearly half of patients reported that their symptoms were very much (33%) or completely resolved (16%) following treatment. The most commonly reported adverse events were sleep disturbance (45%), mood changes (33%), weight gain (29%), and increased appetite (26%). Systematic assessment of relapses and response to relapse treatment may help clinicians to optimize outcomes for MS patients. |
format | Online Article Text |
id | pubmed-3677606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-36776062013-06-13 Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study Perrin Ross, Amy Williamson, Alona Smrtka, Jennifer Flemming Tracy, Tracy Saunders, Carol Easterling, Constance Niewoehner, John Mutschler, Nicole Mult Scler Int Clinical Study There is need for a brief but comprehensive objective assessment tool to help clinicians evaluate relapse symptoms in patients with multiple sclerosis (MS) and their impact on daily functioning, as well as response to treatment. The 2-part Assessing Relapse in Multiple Sclerosis (ARMS) questionnaire was developed to achieve these aims. Part 1 consists of 7 questions that evaluate relapse symptoms, impact on activities of daily living (ADL), overall functioning, and response to treatment for previous relapses. Part 2 consists of 7 questions that evaluate treatment response in terms of symptom relief, functioning, and tolerability. The ARMS questionnaire has been evaluated in 103 patients with MS. The most commonly reported relapse symptoms were numbness/tingling (67%), fatigue (58%), and leg/foot weakness (55%). Over half of patients reported that ADL or overall functioning were affected very much (47%) or severely (11%) by relapses. Prescribed treatments for relapses included intravenous and/or oral corticosteroids (87%) and adrenocorticotropic hormone (13%). Nearly half of patients reported that their symptoms were very much (33%) or completely resolved (16%) following treatment. The most commonly reported adverse events were sleep disturbance (45%), mood changes (33%), weight gain (29%), and increased appetite (26%). Systematic assessment of relapses and response to relapse treatment may help clinicians to optimize outcomes for MS patients. Hindawi Publishing Corporation 2013 2013-05-26 /pmc/articles/PMC3677606/ /pubmed/23766909 http://dx.doi.org/10.1155/2013/470476 Text en Copyright © 2013 Amy Perrin Ross et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Perrin Ross, Amy Williamson, Alona Smrtka, Jennifer Flemming Tracy, Tracy Saunders, Carol Easterling, Constance Niewoehner, John Mutschler, Nicole Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study |
title | Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study |
title_full | Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study |
title_fullStr | Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study |
title_full_unstemmed | Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study |
title_short | Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study |
title_sort | assessing relapse in multiple sclerosis questionnaire: results of a pilot study |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677606/ https://www.ncbi.nlm.nih.gov/pubmed/23766909 http://dx.doi.org/10.1155/2013/470476 |
work_keys_str_mv | AT perrinrossamy assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy AT williamsonalona assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy AT smrtkajennifer assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy AT flemmingtracytracy assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy AT saunderscarol assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy AT easterlingconstance assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy AT niewoehnerjohn assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy AT mutschlernicole assessingrelapseinmultiplesclerosisquestionnaireresultsofapilotstudy |